IL2 and neoplasm: Additionally, low dose (LD) IL-2 treatment preferentially saturates IL-2Rα (CD25), which is highly expressed on regulatory T cells (Tregs), over IL-2Rβ/γ, which is expressed on CD8+ T cells and NK cells; this paradoxically decreases anti-tumor immunity due to Treg activation (11).